Popovici D, Hertoghe J
C. I. Parhon Institute of Endocrinology, Bucharest, Romania.
Endocrinologie. 1991;29(3-4):119-36.
In the present study: (a) physiopathology, (b) clinics, and (c) therapy of cardiothyreosis are discussed. (a) The hyperkinetic syndrome, the earliest clinical sign in thyrotoxicosis (vasodilatation, increase in inotropism, automatism, etc.), is mediated by a two-fold increase in the number of beta-receptors, and supported by an adequate synthesis of ATP and creatinphosphate (CP) in the young and, to a lesser extent, in the elderly. Genetical heart reserves are mobilized, thus significantly increasing the number and the size of mitochondria and also the enzymatic equipment (such as: the alpha-glycerophosphate-dehydrogenase, malic, pentosic cycles, etc.), a.s.o. Due to an excessive adrenergic action (glycogenolysis, an excessive oxygen consumption, up to necrosis, the ATP and CP syntheses dramatically drop; the phosphorus/oxygen ratio decreases to 2 (normal = 4). In this condition, the high functional cardiovascular performances are also impaired (the submaximal effort capacity is attained at a smaller and smaller oxygen consumption; Propranolol 2 mg i.v. decreased the cardiac output by above 30% (vs 10%--normal); electrocardiogram presents aspects of "coronary disease", tachycardia, etc.). An ultrastructural damage occurs: from "mitochondrial disease", partial lysis of myofibrils, to myofibrosis (revealed postmortem), in spite of a reduced degree of coronary atherosclerosis. Ultrastructural and biochemical experimental data support this point of view. (b) The incidence, precocity and severity of the thyrotoxic heart increase with age and the existence of a previous cardiovascular pathology. Cardiothyreosis is not present under 27 years; in 4,353 patients its incidence is of 25% (arrhythmia--21%, heart failure--12%, coronary insufficiency--1-3%). Of a major interest are tachyarrhythmias which may lead to a high mortality by hypodiastolic congestive heart failure, heart failure with secondary hyperaldosteronism, thromboembolic episodes and ventricular fibrillation. Thyrotoxicosis favours the disease of papillary muscles--mitral prolapse and insufficiency, reversible especially in children. (c) The treatment of thyrotoxic heart is an etiologic one (medical, surgical, radioactive--the last two being preferable after the adequate medical therapy). In particular, cardiothyreosis requires a reinforced irradiation (10,000 rads instead of 7,000 rads) in smaller 131I doses. The protection against the increased nocivity of catechols in thyrotoxicosis is very important (which explains the high mortality in the thyrotoxic "storm") and requires propranolol; doses above 2 mg/kilo body/day are recommended. In the elderly, the sensitivity to propranolol decreases: verapamil i.v. is more efficient in paroxysmal tachyarrhythmias (flutter, atrial fibrillation) and in those occurring intra-operatively during halothane narcosis. The anticoagulant therapy is administered in tachyarrhythmias with high ventricular rate, especially in the elderly, to avoid the embolic risk, higher in defibrillation condition.(ABSTRACT TRUNCATED AT 400 WORDS)
(a)讨论了甲状腺毒症性心脏病的生理病理学、(b)临床症状以及(c)治疗方法。(a)甲状腺毒症最早的临床症状即运动亢进综合征(血管舒张、变力性增加、自律性增强等),是由β受体数量增加两倍介导的,并且在年轻人中,以及在较小程度上在老年人中,由三磷酸腺苷(ATP)和磷酸肌酸(CP)的充分合成所支持。遗传心脏储备被调动起来,从而显著增加线粒体的数量和大小以及酶设备(如:α-甘油磷酸脱氢酶、苹果酸、戊糖循环等)等。由于肾上腺素能作用过度(糖原分解、氧消耗过多,直至坏死,ATP和CP合成急剧下降;磷/氧比值降至2(正常为4)。在这种情况下,高功能性心血管表现也会受损(在越来越少的氧消耗时达到次最大运动能力;静脉注射2毫克普萘洛尔使心输出量降低超过30%(相比正常情况的10%);心电图呈现“冠心病”、心动过速等表现)。会发生超微结构损伤:从“线粒体疾病”、肌原纤维部分溶解到肌纤维纤维化(尸检时发现),尽管冠状动脉粥样硬化程度降低。超微结构和生化实验数据支持这一观点。(b)甲状腺毒症性心脏病的发病率、早熟性和严重程度随年龄以及既往心血管疾病的存在而增加。27岁以下不存在甲状腺毒症性心脏病;在4353名患者中其发病率为25%(心律失常——21%,心力衰竭——12%,冠状动脉供血不足——1 - 3%)。特别值得关注的是快速性心律失常,其可能因舒张期低血压性充血性心力衰竭、继发性醛固酮增多症性心力衰竭、血栓栓塞事件和心室颤动导致高死亡率。甲状腺毒症有利于乳头肌疾病——二尖瓣脱垂和关闭不全,尤其在儿童中是可逆的。(c)甲状腺毒症性心脏病的治疗是病因性治疗(药物、手术、放射性——后两种在充分的药物治疗后更可取)。特别是,甲状腺毒症性心脏病需要在较小的131I剂量下进行强化照射(10000拉德而非7000拉德)。防止甲状腺毒症中儿茶酚胺毒性增加非常重要(这解释了甲状腺毒症“风暴”中的高死亡率),并且需要普萘洛尔;建议剂量高于2毫克/千克体重/天。在老年人中,对普萘洛尔的敏感性降低:静脉注射维拉帕米对阵发性快速性心律失常(扑动、心房颤动)以及在氟烷麻醉术中发生的心律失常更有效。在心室率高的快速性心律失常中,尤其是在老年人中,进行抗凝治疗以避免栓塞风险,在除颤情况下栓塞风险更高。(摘要截断于400字)